Pharmacy Week in Review: December 4, 2015

Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.

Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.

RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.

ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.

The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.

Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.

A pharmacy technician reflects on 3 patient encounters that reshaped his understanding of what a real patient requires.

Treated patients also had fewer postacute hospitalizations and deaths, but individuals without risk factors saw no benefit.